Synthesis and Biological Assessment of PyrimidoTacrines as Promising Agents for Alzheimer's Disease Therapy

Affiliation auteurs!!!! Error affiliation !!!!
TitreSynthesis and Biological Assessment of PyrimidoTacrines as Promising Agents for Alzheimer's Disease Therapy
Type de publicationJournal Article
Year of Publication2021
AuteursDakhlaoui I, Maalej E, Martin H, Lucht A, Iriepa I, Moraleda I, Marco-Contelles J, Chabchoub F, Ismaili L
JournalCHEMISTRYSELECT
Volume6
Pagination9975-9980
Date PublishedOCT 6
Type of ArticleArticle
ISSN2365-6549
Mots-clésAlzheimer disease, Hepatotoxicity, multitarget small molecules, Pyrimidotacrine, tacrine analogues
Résumé

Considering the multifactorial nature of Alzheimer's disease (AD), multitarget small molecules (MTSMs) represent the most potent and attractive therapeutic strategy to design new drugs for Alzheimer's disease therapy. Thus, new Pyrimidotacrines were designed and synthesized by merging pyrimidine scaffold and tacrine. Among them, 4-(4-nitrophenyl)-2-phenyl-6,7,8,9-tetrahydropyrimido[4,5-b]quinolin-5 -amine (4 j) was identified as less hepatotoxic than tacrine at high concentration, a submicromolar inhibitor against both acetylcholinesterase (AChE) (IC50=677 +/- 28 nM) and butyrylcholinesterase (BuChE) (IC50=756 +/- 41 nM) showing potent antioxidant properties (2.43 TE) and displaying a strong neuroprotection effect against hydrogen peroxide (H2O2) and Oligomycin Rotenone. Consequently, 4 j is a potential new hit-ligand for AD therapy for further biological exploration

DOI10.1002/slct.202102363